These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 17171)

  • 21. [Results of clinical testing of carbochromen in chronic coronary insufficiency].
    Schvacabaja IK; Mjasnikov LA; Metelica VI; Grigorjanc RA
    Arzneimittelforschung; 1970 Mar; 20():449-51. PubMed ID: 4916579
    [No Abstract]   [Full Text] [Related]  

  • 22. [Hemodynamic and humoral changes following intravenous administration of xamoterol in patients with heart failure and coronary heart disease].
    Erlemeier HH; Kupper W; Bleifeld W
    Z Kardiol; 1990 Feb; 79(2):126-33. PubMed ID: 1969685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hemodynamics and myocardial metabolism in coronary disease during beta receptor stimulation and administration of postassium magnesium aspartate (PMA)].
    Kühn P; Probst P
    Verh Dtsch Ges Kreislaufforsch; 1975; 41():148-51. PubMed ID: 7885
    [No Abstract]   [Full Text] [Related]  

  • 24. [The value of xamoterol in moderate ischemic cardiac insufficiency].
    Rousseau MF; Cheron P; Vincent MF; Pouleur H; Lavenne F
    Ann Cardiol Angeiol (Paris); 1984; 33(4):215-8. PubMed ID: 6147115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Long-term effect of a new beta-agonist prenalterol in patients with severe congestive heart failure (author's transl)].
    Lambertz H; Erbel R; Meyer J; Schweizer P; Effert S
    Z Kardiol; 1982 Jan; 71(2):65-74. PubMed ID: 6122313
    [No Abstract]   [Full Text] [Related]  

  • 26. [Beta-receptor blockers in ischemic heart disease: the pathophysiological and clinical aspects].
    Urbaszek W; Modersohn D
    Z Arztl Fortbild (Jena); 1979 Feb; 73(3):101-6. PubMed ID: 34938
    [No Abstract]   [Full Text] [Related]  

  • 27. [Treatment of a stable form of coronary disease with Adalat retard].
    Kraska T; Korewicki J; Niemczyk M; Opolski G; Jakubowska-Najnigier M; Słomka K; Zieliński T
    Pol Tyg Lek; 1986 Mar; 41(9):277-9. PubMed ID: 3520520
    [No Abstract]   [Full Text] [Related]  

  • 28. [Effect of riboxin on hemodynamics and microcirculation in patients with chronic ischemic heart disease].
    Bondarenko IP
    Vrach Delo; 1983 Jan; (1):15-8. PubMed ID: 6868490
    [No Abstract]   [Full Text] [Related]  

  • 29. [Effect of isoptin on hemodynamics in patients with hypertension and ischemic heart disease].
    Zaslavskaia RM; Budenova LA; Vilkovyskiĭ FA; Malkin LM; Olevskiĭ IKh
    Klin Med (Mosk); 1985 Aug; 63(8):33-6. PubMed ID: 3908807
    [No Abstract]   [Full Text] [Related]  

  • 30. [Evaluation of the effectiveness of bricanyl].
    Ubaĭdullaev AM; Makhmudova DKh; Iakimova MA; Islamkhodzhaev PS
    Ter Arkh; 1980; 52(11):130-2. PubMed ID: 6110247
    [No Abstract]   [Full Text] [Related]  

  • 31. [No taboo for heart patients].
    MMW Fortschr Med; 2002 Aug; 144(31-32):51. PubMed ID: 12422736
    [No Abstract]   [Full Text] [Related]  

  • 32. [Cordaron and nonachlasine in treatment of chronic coronary insufficiency].
    Metelitsa VI; Matveeva LS; Borisova GA; Lupanov VP
    Kardiologiia; 1975 Jul; 15(7):48-51. PubMed ID: 1570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical trials and ischaemic heart disease: can drugs reduce coronary mortality?
    Silke B; Nelson GI; Taylor SH
    Ir Med J; 1982 Aug; 75(8):297-303. PubMed ID: 6127330
    [No Abstract]   [Full Text] [Related]  

  • 34. Pathophysiological mechanisms underlying the effects of beta-adrenergic agonists and antagonists on functional capacity and survival in chronic heart failure.
    Packer M
    Circulation; 1990 Aug; 82(2 Suppl):I77-88. PubMed ID: 1973643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy of xamoterol in heart failure of ischemic origin.
    Marlow HF
    J Cardiovasc Pharmacol; 1989; 14 Suppl 5():S69-72. PubMed ID: 2478814
    [No Abstract]   [Full Text] [Related]  

  • 36. [Effect of ildamen on the heart conduction system in ischemic heart disease patients].
    Shilov AM; Borisov VG
    Farmakol Toksikol; 1987; 50(5):34-6. PubMed ID: 2891566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Use of coronaroactive agents with beta-stimulating effect in ischemic heart disease].
    Kukes VG; Buianov VV; Semenov VN; Abugov AM; Borovkov AI
    Kardiologiia; 1976 Apr; 16(4):88-93. PubMed ID: 16157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Double-blind clinical trial of a new coronary-active drug, MD 6753].
    Dalla Volta S
    Minerva Cardioangiol; 1974 Oct; 22(10):683-90. PubMed ID: 4215049
    [No Abstract]   [Full Text] [Related]  

  • 39. [The use of propranolol and verapamil in patients with ischemic heart disease].
    Chizh VD
    Vrach Delo; 1990 Feb; (2):15-8. PubMed ID: 2339541
    [No Abstract]   [Full Text] [Related]  

  • 40. [Effect of anabolic steroids and adrenergic beta receptor blockaders on the indicators of rheogram of the aorta and lungs in patients with ischemic heart disease].
    Sharlaĭ IR
    Vrach Delo; 1974 Aug; 0(8):15-7. PubMed ID: 4153197
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.